CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Urine collectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug1262 Isoniazid, Rifampicin, Pyrazinamide and Ethambutol Wiki 1.00
drug365 Blood Collection Wiki 1.00
drug1732 PET/CT Scan Wiki 1.00
drug2291 Sputum collection Wiki 1.00
drug2187 Saliva collection Wiki 0.45

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D014397 Tuberculosis, Pulmonary NIH 1.00
D014376 Tuberculosis NIH 0.71

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Using Biomarkers to Predict TB Treatment Duration

Background: Tuberculosis (TB) is a bacterial lung infection. Typical treatment using anti-TB drugs lasts about 6 months. Some people with less severe TB might not need to take the drugs that long. Researchers think a PET/CT lung scan along with estimating how much TB is in the lungs might show who will be cured after only 4 months of treatment. Objective: To demonstrate that 4 months of treatment is not inferior to 6 months of treatment for people with less severe TB. Eligibility: People 18-75 years old who have TB treatable with standard TB drugs Design: Participants will be screened with: Medical history Physical exam Blood and urine tests HIV test Sputum sample: Participants will be asked to cough sputum into a cup. Chest x-ray Participants will start TB drugs. They will have visits at weeks 1, 2, 4, 8, 12, and about 6 more times during the 18-month study. Visits include: Sputum samples Physical exam Blood tests PET/CT scans at 2-3 visits: Participants fast for about 6 hours before the scan. Participants get FDG, a type of sugar that gives off a small amount of radiation, through an arm vein. They lie on a table in a machine that takes pictures of the body. Chest x-rays at 1-2 visits Participants who we believe are likely to be cured at 4 months will be randomly assigned to get either 6 months of treatment or 4 months of treatment. Participants may be asked to join a substudy using their sputum samples or additional blood tests.

NCT02821832 Pulmonary Tuberculosis Procedure: Saliva collection Procedure: Urine collection Procedure: Sputum collection Procedure: Blood Collection Radiation: PET/CT Scan Drug: Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
MeSH:Tuberculosis Tuberculosis, Pulmonary

Primary Outcomes

Description: Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm.

Measure: Comparison of the rate of treatment success at 18 months (after treatment initiation) between Arms B and C.

Time: 18 months

Secondary Outcomes

Description: The difference (and 95% confidence interval) in treatment success rates between a combined A+B Arm (with Arm A participants selected to represent a true 6-month standard of care population) and a combined Arm A+C (with the remaining Arm A participants selected to represent a treatment shortening strategy arm, and no overlap in Arm A participants assigned to B and C).

Measure: Radiologic, Immunologic and microbiologic measures

Time: 18 months


No related HPO nodes (Using clinical trials)